Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ZYUS Life Sciences ( (TSE:ZYUS) ) has shared an update.
ZYUS Life Sciences Corporation announced the closing of its non-brokered private placement, raising approximately $0.75 million through the issuance of 1,116,267 units. The proceeds will be used for general corporate and working capital purposes. The offering received conditional approval from the TSX Venture Exchange and involved insider participation, which was deemed a related party transaction. The company’s strategic financial maneuver aims to bolster its operational capabilities and enhance its market positioning in the cannabinoid-based pharmaceutical industry.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company that focuses on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to securing intellectual property protection and obtaining regulatory approval for non-opioid-based pharmaceutical solutions to transform patients’ lives.
Average Trading Volume: 18,446
Technical Sentiment Signal: Sell
Current Market Cap: C$47.74M
For an in-depth examination of ZYUS stock, go to TipRanks’ Overview page.